Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Retinal layer thinning rate as a biomarker predicting treatment response in relapsing multiple sclerosis
Multiple Sclerosis
P12 - Poster Session 12 (12:00 PM-1:00 PM)
9-009
We aimed to investigate the potential of retinal layer thinning for prediction of treatment response in relapsing multiple sclerosis (RMS).
Peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell plus inner plexiform layer (mGCIPL) thinning are markers of neuroaxonal degeneration in MS. pRNFL and mGCIPL thinning is more pronounced in patients with physical or cognitive disability progression, while it is reduced by disease-modifying treatment (DMT).
In this 5-year prospective observational study on 113 RMS patients, pRNFL and GCIPL were measured at DMT initiation and after 12 (M12) and 24 months (M24) of follow-up by spectral-domain optical coherence tomography (OCT). Inclusion criteria included adherence to DMT for at least 2 years. Patients suffering optic neuritis between baseline and M24 were excluded. Treatment response was defined as absence of 6 month confirmed EDSS progression and Symbol Digit Modalities Test (SDMT) worsening during the observation period. Best possible cut-off values of retinal thinning for predicting treatment response were determined by receiver-operating characteristics (ROC) analyses. Odds ratios (OR) for treatment response were calculated by multivariate logistic regression models correcting for age, sex, disease duration and EDSS/SDMT at baseline.
Thinning of mGCIPL<0.5mm at M24 displayed superior prediction of treatment response (odds ratio [OR] 4.5; 95% confidence interval [CI]: 1.8 – 7.6; p<0.001; specificity 91%, sensitivity 81%) followed by mGCIPL <0.3mm at M12 (OR 3.9; 95% CI: 1.4 – 6.9; p<0.001; specificity 85%, sensitivity 78%), pRNFL <2mm at M24 (OR 3.7; 95% CI: 1.1 – 6.5; p=0.023; specificity 84%, sensitivity 69%), while pRNFL at M12 was not significantly predictive.
mGCIPL – and to a lesser degree pRNFL – thinning predict physical and cognitive disability progression upon DMT initiation. Pending validation, retinal layer thinning may be a useful and easily accessible biomarker of treatment responsein RMS.
Authors/Disclosures
Gabriel Bsteh, MD (Medical University Vienna, Department of Neurology)
PRESENTER 		Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi.
Harald Hegen, MD Dr. Hegen has nothing to disclose.
Klaus Berek, MD (Ao.BKH-Kufstein) No disclosure on file
Patrick Altmann (Univ.-Klinik für Neurologie) The institution of Mr. Altmann has received research support from Quanterix. The institution of Mr. Altmann has received research support from Biogen, Merck, Roche, Sanofi, Teva,. Mr. Altmann has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
Michael Auer Michael Auer has nothing to disclose.
Franziska Di Pauli Franziska Di Pauli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jannsen. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for horizon. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for merck. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jannsen. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Franziska Di Pauli has received research support from Roche.
No disclosure on file
Berthold Pemp, MD (Medical University of Vienna) Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi. Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chiesi. Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GenSight. The institution of Dr. Pemp has received research support from Chiesi.
Florian Deisenhammer, MD Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Deisenhammer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS/Celgene. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Almirall. Dr. Deisenhammer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Celgene. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Deisenhammer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SOBI.
Thomas A. Berger, MD (Dept. of Neurology, Medical University of Vienna) Prof. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a speaker at scientific meetings and participant of local and international advisory boards with various companies producing and markerting treatments for multiple sclerosis (Almirall, Biogen, Biologix, Bionorica, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme, TG Therapeutics, UCB).